| Zhou, Caicun |
Orient-12, NCT03629925: Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC |
|
|
| Completed | 3 | 357 | RoW | Sintilimab, IBI308, Gemcitabine, Cisplatin, Placebo, Carboplatin | Innovent Biologics (Suzhou) Co. Ltd. | Squamous NSCLC | 03/20 | 09/21 | | |
|
|
|
|
| Completed | 3 | 805 | Europe, RoW | Tislelizumab, BGB-A317, Docetaxel | BeiGene | Non-small Cell Lung Cancer | 08/20 | 01/24 | | |
|
|
|
|
|
|
CameL-sq, NCT03668496: A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC |
|
|
| Active, not recruiting | 3 | 390 | RoW | SHR-1210, The placebo | Jiangsu HengRui Medicine Co., Ltd. | Lung Cancer Squamous Cell, Lung Cancer Stage IV, PD-1 Antibody, Chemotherapy Effect | 11/20 | 12/21 | | |
EVIDENCE, NCT02448797: Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation |
|
|
| Active, not recruiting | 3 | 320 | RoW | Icotinib, Conmana, Chemotherapy, Navelbine, ALIMTA | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/22 | 12/23 | | |
| Active, not recruiting | 3 | 482 | RoW | KN046, KN046 placebo | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Squamous Non-small-cell Lung Cancer | 08/22 | 08/23 | | |
NCT04619433: A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. |
|
|
| Recruiting | 3 | 560 | RoW | Camrelizumab;Pemetrexed and Carboplatin; Famitinib;, SHR1210, Camrelizumab;Pemetrexed and Carboplatin;Placebo | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous Non-small-cell Lung Cancer | 12/22 | 10/23 | | |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
| Recruiting | 3 | 500 | RoW | Pemetrexed, Carboplatin, Paclitaxel, Sintilimab, Cisplatin, Nab paclitaxel, Placebo | Innovent Biologics (Suzhou) Co. Ltd. | Non-Small Cell Lung Cancer | 09/26 | 10/28 | | |
NCT05042375: A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 450 | RoW | camrelizumab + famitinib, pembrolizumab, camrelizumab | Jiangsu HengRui Medicine Co., Ltd. | Non-small Cell Lung Cancer | 12/23 | 12/25 | | |
SKB264-Ⅲ-12, NCT06448312: A Study of SKB264 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 406 | RoW | SKB264, Pembrolizumab | Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | Non-Small Cell Lung Cancer | 11/26 | 11/26 | | |
| Active, not recruiting | 3 | 398 | RoW | AK112, Pembrolizumab | Akeso | Advanced Non-small-cell Lung Cancer | 06/24 | 06/25 | | |
NCT06031558: Phase III Study of SY-5007, a RET Inhibitor, in Patients With Locally Advanced or Metastatic RET Fusion-positive NSCLC |
|
|
| Recruiting | 3 | 120 | RoW | SY-5007, SY-5007 tablets | Shouyao Holdings (Beijing) Co. LTD | Non-Small Cell Lung Cancer | 09/24 | 06/26 | | |
NCT05673590: Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Recruiting | 3 | 612 | RoW | Utidelone Injection, Docetaxel Injection | Beijing Biostar Pharmaceuticals Co., Ltd. | Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 06/25 | 12/25 | | |
NCT05668988: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) |
|
|
| Recruiting | 3 | 320 | Europe, Canada, US, RoW | DZD9008, Pemetrexed+carboplatin | Dizal Pharmaceuticals | Non-small Cell Lung Cancer | 02/26 | 10/27 | | |
NCT06080776: SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations |
|
|
| Recruiting | 3 | 242 | RoW | SH-1028 tablets, Placebo SH-1028 tablets | Nanjing Sanhome Pharmaceutical, Co., Ltd. | Non-small Cell Lung Cancer | 02/28 | 02/31 | | |
DUBHE-L-304, NCT05487391: A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. |
|
|
| Not yet recruiting | 3 | 632 | NA | QL1706 injection, Vinorelbine Tartrate, Paclitaxel, Cisplatin, Carboplatin, Pemetrexed, Placebo | Qilu Pharmaceutical Co., Ltd. | Carcinoma, Non-Small-Cell Lung | 10/28 | 10/31 | | |
NCT04750083: HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | 2/3 | 700 | RoW | HX008, Pembrolizumab, pemetrexed, cisplatin/carboplatin | Taizhou Hanzhong biomedical co. LTD | Nonsquamous Non-small Cell Lung Cancer | 09/22 | 09/23 | | |
NCT05001724: KN046 Plus Lenvatinib in Subject With Advanced Non-Small Cell Lung Cancer in the Failure of Anti-PD-(L)1 Agent |
|
|
| Terminated | 2/3 | 16 | RoW | KN046, Lenvatinib, Docetaxel | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Advanced Non-small Cell Lung Cancer | 02/23 | 04/23 | | |
NCT03904823: A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLC |
|
|
| Recruiting | 2 | 58 | RoW | famitinib po, HS-10296 po | Jiangsu HengRui Medicine Co., Ltd. | EGFR-mutant Non-Small Cell Lung Cancer | 12/22 | 12/22 | | |
NCT05519865: A Study of Tucidinostat Combined With Tislelizumab as First-line Treatment in Advanced NSCLC |
|
|
| Recruiting | 2 | 114 | RoW | Tucidinostat, Chidamide, CS055, Tislelizumab | Chipscreen Biosciences, Ltd. | Non Small Cell Lung Cancer | 10/23 | 10/24 | | |
| Not yet recruiting | 2 | 60 | RoW | BL-B01D1, PD-1 monoclonal antibody | Sichuan Baili Pharmaceutical Co., Ltd., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd. | Extensive-stage Small-cell Lung Cancer | 06/26 | 06/26 | | |
NCT04211922: Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib |
|
|
| Terminated | 2 | 4 | RoW | Alkotinib Capsules, ZG0418 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | ALK-positive Non-small Cell Lung Cancer | 10/22 | 10/22 | | |
NCT05168566: Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 99 | US, RoW | Sutetinib Maleate Capsule, Sutetinib | Teligene US | Non-small Cell Lung Cancer | 08/24 | 02/25 | | |
YH001, NCT05212922: A Study to Evaluate in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC |
|
|
| Withdrawn | 2 | 80 | Europe, RoW | YH001 + Toripalimab | Eucure (Beijing) Biopharma Co., Ltd | HCC, NSCLC Stage IIIB, NSCLC Stage IV | 12/24 | 03/25 | | |
NCT05880706: A Study of BL-B01D1 Combined With Osimertinib Mesylate Tablets in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 2 | 42 | RoW | BL-B01D1, Osimertinib Mesylate Tablets | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 07/25 | 07/25 | | |
| Recruiting | 1/2 | 108 | RoW | AK112 | Akeso | Non-small Cell Lung Cancer | 05/23 | 05/24 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT06243354: Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation |
|
|
| Recruiting | 1/2 | 257 | RoW | Test product: HYP-2090PTSA | Sichuan Huiyu Pharmaceutical Co., Ltd | Safety, Tolerability, Efficacy | 12/25 | 12/25 | | |
NCT06306456: A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC |
|
|
| Recruiting | 1/2 | 94 | RoW | GH21+Osimertinib, GH21 Capsules Combined with Osimertinib Mesylate Tablets | Suzhou Genhouse Bio Co., Ltd. | Non-Small Cell Lung Cancer With EGFR Mutation | 12/25 | 12/26 | | |
NCT06385678: A Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
|
|
| Not yet recruiting | 1/2 | 70 | RoW | HRS-4642, Adebrelimab, SHR-A1921, Pemetrexed Disodium for Injection、Cisplatin Injection、Carboplatin for Injection | Jiangsu HengRui Medicine Co., Ltd. | Advanced KRAS G12D Mutant Solid Tumors | 10/25 | 08/26 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
TRIGGERCD8, NCT06468358: A Study to Evaluate LB1410 in Combination With LB4330 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Not yet recruiting | 1/2 | 194 | RoW | LB1410, LB4330 | L & L biopharma Co., Ltd., Shanghai China, Shanghai East Hospital | Solid Tumor | 12/26 | 12/27 | | |
NCT05278364: Phase I/II Study of SY-5007, a RET Inhibitor, in Patients With RET-altered Advanced Solid Tumor |
|
|
| Recruiting | 1/2 | 184 | RoW | SY-5007, SY-5007 Capsule | Shouyao Holdings (Beijing) Co. LTD | Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Solid Tumor | 01/25 | 02/25 | | |
NCT05223231: Evaluation of LBL-019 Monotherapy or Combined With Anti-PD-1 Antibody in the Treatment of Advanced Malignant Tumors |
|
|
| Recruiting | 1/2 | 486 | RoW | LBL-019 Injection, LBL-019, anti-PD-1 antibody injection, anti-PD-1 antibody | Nanjing Leads Biolabs Co.,Ltd | Advanced Malignant Tumors | 03/25 | 10/25 | | |
Triumph-02, NCT05978401: Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer |
|
|
| Not yet recruiting | 1/2 | 152 | RoW | GLS-012+GLS-010, LAG3, PD-1, GLS-012+GLS-010+pemetrexed+carboplatin, chemotherapy, GLS-012+GLS-010+paclitaxel+carboplatin | Guangzhou Gloria Biosciences Co., Ltd. | Advanced Non-Small Cell Lung Cancer | 04/25 | 04/26 | | |
| Recruiting | 1/2 | 233 | RoW | AK112, AK104, Carboplatin, paclitaxel, pemetrexed, Docetaxel | Akeso | Advanced Non-small-cell Lung Cancer | 04/25 | 01/27 | | |
NCT05949619 / CTR20232085: Phase Ib/II clinical study of BL-M02D1 in patients with locally advanced or metastatic non-small cell lung cancer and other solid tumors |
|
|
| Not yet recruiting | 1/2 | 60 | RoW | BL-M02D1 - Biokin Pharma | Sichuan Baili Pharmaceutical Co., Ltd. | Locally advanced or metastatic non-small cell lung cancer or other solid tumors | 08/25 | 08/25 | | |
NCT05949606: A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 160 | RoW | SI-B001, SI-B003 | Sichuan Baili Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 11/25 | 11/25 | | |
NCT05994131: IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC |
|
|
| Recruiting | 1/2 | 110 | RoW | IN10018, BI 853520, Furmonertinib | InxMed (Shanghai) Co., Ltd. | NSCLC | 07/26 | 07/26 | | |
NCT04085185: A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors |
|
|
| Recruiting | 1a | 268 | RoW | IBI110, IBI110+ Sintilimab | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Malignancies | 12/23 | 06/24 | | |
NCT03852823: Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours |
|
|
| Recruiting | 1 | 192 | RoW | SG001, Recombinant Human Anti-PD-1 Monoclonal Antibody | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Advanced Solid Tumours, Cervical Cancer, Malignant Mesothelioma, Lymphoma, Non-Small-Cell Lung Cancer | 09/22 | 03/23 | | |
NCT05058352: A Study of HS269 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 36 | RoW | HS269 | Zhejiang Hisun Pharmaceutical Co. Ltd. | Advanced Solid Tumor | 10/22 | 04/23 | | |
NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors |
|
|
| Recruiting | 1 | 150 | RoW | GQ1005 | GeneQuantum Healthcare (Suzhou) Co., Ltd. | HER2 Expressing or Mutated Advanced Malignant Solid Tumors | 12/24 | 07/25 | | |
NCT06231550: A Study of Axl Inhibitor FC084CSA in Patients With Advanced Malignant Solid Tumors |
|
|
| Recruiting | 1 | 43 | RoW | FC084CSA tablets | FindCure Biosciences (ZhongShan) Co., Ltd. | Advanced Malignant Solid Tumors | 12/24 | 02/25 | | |
NCT05198505: Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors |
|
|
| Recruiting | 1 | 280 | RoW | TQB2868 Injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Advanced Malignant Tumor | 06/23 | 06/24 | | |
NCT06132828: Evaluate the Safety, Tolerability, Pharmacokinetics of DR30206 in Patients With Advanced or Metastatic Solid Tumors |
|
|
| Recruiting | 1 | 182 | RoW | DR30206 | Zhejiang Doer Biologics Co., Ltd. | Solid Tumor | 03/26 | 07/26 | | |
NCT05650385: A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 68 | RoW | B1962 | Tasly Biopharmaceuticals Co., Ltd. | Neoplasms Malignant | 12/23 | 10/25 | | |
| Recruiting | 1 | 156 | US, RoW | CS5001 | CStone Pharmaceuticals | Advanced Solid Tumor, Advanced Lymphoma | 03/25 | 06/25 | | |
| Recruiting | 1 | 96 | US, RoW | GQ1001 | GeneQuantum Healthcare (Suzhou) Co., Ltd., Conjugate Light (Australia) Pty Ltd | HER2-positive Breast Cancer, HER2-positive Biliary Tract Cancer, HER2-Positive Salivary Gland Carcinomas, HER2-Positive Advanced Solid Tumor | 03/24 | 05/24 | | |
NCT04913285: A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors |
|
|
| Recruiting | 1 | 400 | Europe, US, RoW | KIN-2787, exarafenib, KIN-2787 and binimetinib, exarafenib and binimetinib | Pierre Fabre Medicament | Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma | 12/24 | 12/25 | | |
NCT06298058: A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients. |
|
|
| Not yet recruiting | 1 | 144 | NA | SIBP-A13 formulation for injection, Her3-ADC | Shanghai Institute Of Biological Products, Shanghai Pulmonary Hospital, Shanghai, China | Advanced Solid Tumor | 04/26 | 06/26 | | |
| Recruiting | 1 | 250 | RoW | QLC1101 | Qilu Pharmaceutical Co., Ltd. | Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Cancer, Solid Tumor | 05/26 | 04/27 | | |
NCT05533463: Phase I Study of HRS-4642 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation |
|
|
| Recruiting | 1 | 108 | RoW | HRS-4642 | Jiangsu HengRui Medicine Co., Ltd. | Advanced KRAS G12D Mutant Solid Tumors | 04/24 | 12/24 | | |
NCT05306132: Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 |
|
|
| Recruiting | 1 | 150 | RoW | ASKC202 | Jiangsu Aosaikang Pharmaceutical Co., Ltd. | Advanced Solid Tumor | 05/24 | 05/25 | | |
NCT06424665: A Study of FZ-AD005 in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 162 | RoW | FZ-AD005 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma) | 12/25 | 06/26 | | |
NCT05370755: A Study of ICP-189 and ICP-189 in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 22 | RoW | ICP-189 | Beijing InnoCare Pharma Tech Co., Ltd. | Patients With Advanced Solid Tumors | 05/24 | 01/26 | | |
NCT05357651: A Study to Assess the Safety and Efficacy of LB1410 in Participants With Advanced Solid Tumor or Lymphoma（Keyplus-001） |
|
|
| Recruiting | 1 | 100 | RoW | LB1410 | L & L biopharma Co., Ltd., Shanghai China | Solid Tumor, Lymphoma | 12/24 | 03/25 | | |
NCT06006793: A Study of SY-5933 in Patients With Advanced Solid Tumors Harboring the KRAS p.G12C Mutation |
|
|
| Recruiting | 1 | 50 | RoW | SY-5933, SY-5933 tablet | Shouyao Holdings (Beijing) Co. LTD | Advanced Solid Tumor | 02/25 | 08/25 | | |
NCT05772455: A Study of XZB-0004 in Patients With Solid Tumors |
|
|
| Not yet recruiting | 1 | 128 | RoW | XZB-0004 | Xuanzhu Biopharmaceutical Co., Ltd. | Advanced Solid Tumor, NSCLC | 06/25 | 02/27 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Recruiting | 1 | 72 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 08/25 | 08/25 | | |
NCT06050980: Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation |
|
|
| Recruiting | 1 | 220 | RoW | HSK40118 | Haisco Pharmaceutical Group Co., Ltd. | NSCLC | 08/25 | 06/27 | | |
NCT04360655: Bronchoscopic Microwave Intervention Treatment in Advanced Central NSCLC |
|
|
| Not yet recruiting | N/A | 50 | NA | bronchoscopic microwave intervention, Local treatment, anti-PD-1 / PD-L1 monoclonal antibody and chemotherapy, Systemic treatment | Shanghai Pulmonary Hospital, Shanghai, China | Effect Increased, Safety Issues | 04/22 | 05/23 | | |
NCT04137718: Multicenter Observational Study of Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Rare Driver Gene Mutation |
|
|
| Recruiting | N/A | 50000 | RoW | nonIntervention | Shanghai Pulmonary Hospital, Shanghai, China | Chinese, Non-Small Cell Lung Cancer | 10/22 | 10/24 | | |
Brilliant, NCT05721950: A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC) |
|
|
| Recruiting | N/A | 200 | RoW | Brigatinib, Alunbrig | Takeda | Non-small Cell Lung Cancer (NSCLC) | 12/24 | 12/26 | | |
| Zhang, Jie |
NCT04624854: Dual Anti-Platelet Therapy in Patients With Coronary Multi-Vessel Disease (DAPT-MVD) |
|
|
| Active, not recruiting | 4 | 8250 | RoW | Clopidogrel and Aspirin dual-antiplatelet therapy, Aspirin monotherapy | Harbin Medical University, Chinese Society of Cardiology, Lepu Medical Technology (Beijing) Co., Ltd. | Coronary Artery Disease, Myocardial Ischemia, Acute Coronary Syndrome, Heart Diseases, Syndrome Heart Disease, Cardiovascular Diseases, Arteriosclerosis, Arterial Occlusive Diseases, Coronary Disease, Vascular Diseases | 04/25 | 04/25 | | |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection |
|
|
| Recruiting | 3 | 80 | RoW | Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 03/26 | 03/26 | | |
| Active, not recruiting | 3 | 806 | Europe, Canada, Japan, US, RoW | Placebo, Mepolizumab | GlaxoSmithKline, PPD | Pulmonary Disease, Chronic Obstructive | 08/24 | 08/24 | | |
|
|
|
|
|
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 10/26 | 07/31 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
|
|
| Recruiting | 3 | 6000 | Europe, Canada, Japan, US, RoW | Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane | Eli Lilly and Company | Breast Neoplasms | 10/27 | 03/32 | | |
NCT04147208: Evaluate the Safety, Tolerability, and Antiviral Activity of GLS4 With Ritonavir in Patients With Chronic HBV Infection |
|
|
| Completed | 2 | 250 | RoW | GLS4, Morphothiadine Mesilate Capsules, RTV, Ritonavir tablet, ETV, Entecavir table | Sunshine Lake Pharma Co., Ltd. | Chronic HBV Infection | 06/22 | 09/23 | | |
NCT06009861: Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) |
|
|
| Recruiting | 2 | 110 | RoW | Tislelizumab, Albumin-Bound Paclitaxel, Cisplatin | Peking University Hospital of Stomatology | Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | 06/24 | 08/27 | | |
NCT06106685: Washed Microbiota Transplantation for Chronic Constipation in Adults |
|
|
| Recruiting | 1/2 | 18 | RoW | High-dose washed microbiota suspension, WMT-001, Low-dose washed microbiota suspension, Placebo | The Second Hospital of Nanjing Medical University | Constipation | 07/26 | 12/26 | | |
NCT06002425: Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models |
|
|
| Recruiting | N/A | 400 | Europe, US, RoW | Clinician-Directed Treatment Plan, ChatGPT-Assisted Treatment Plan | Chinese Academy of Sciences, ZhuHai Hospital, Fifth Affiliated Hospital, Sun Yat-Sen University, Jiangmen Central Hospital, Peking University Cancer Hospital (Inner Mongolia Campus), San Raffaele University Hospital, Italy, University Hospital Magdeburg, Germany, City of Hope Medical Center | Gastrointestinal Neoplasm Malignant | 09/23 | 12/28 | | |
NCT06141512: Improvements in Aerobic Fitness With Exercise Training: the Role of Myokines |
|
|
| Recruiting | N/A | 24 | Europe | Reduced-exertion high-intensity interval training (REHIT), Sprint interval training (SIT) | University of Stirling | General Health | 04/25 | 06/25 | | |
NCT03641391: Awake Intraoperative Language Mapping and Chinese Probabilistic Map Construction |
|
|
| Not yet recruiting | N/A | 300 | RoW | Intraoperative direct cortical electrical stimulation, Intraoperative direct subcortical electrical stimulation | Huashan Hospital, Shanghai Zhongshan Hospital, Huashan Hospital North, Fudan University | Glioma | 12/23 | 12/23 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
NCT03808779: A Multicenter Trial of Radiofrequency Ablation vs. Surgery as Treatment of Papillary Thyroid Microcarcinoma. |
|
|
| Recruiting | N/A | 200 | RoW | Radiofrequency Ablation, RFA, Conventional Surgery, Total thyroidectomy/Thyroid lobectomy | Second Affiliated Hospital, School of Medicine, Zhejiang University | Papillary Thyroid Microcarcinoma | 02/24 | 02/24 | | |
NCT06106698: Washed Microbiota Transplantation for Clostridioides Difficile Infection |
|
|
| Recruiting | N/A | 100 | RoW | WMT | The Second Hospital of Nanjing Medical University | Clostridioides Difficile Infection | 07/29 | 12/29 | | |
| Wu, Fengying |
| No trials found |
| Qi, Huiwei |
| No trials found |
